Ethical Conflicts in Industry-Sponsored Genetic Testing for Underserved Health Systems
Voices in Bioethics · 2026-10-02 · 12
DOI: 10.52214/5rngr105 ↗Abstract
Photo ID 64616115 © Sergunt | Dreamstime.com Abstract Genetic testing is essential for diagnosing and managing many rare diseases. Testing for high-risk alleles can predict disease decades before symptoms arise and treatment may be too late. However, cost, limited specialist availability, and health system capacity make patients’ access to this testing unequal. Industry-sponsored genetic testing (IST), in which commercial entities provide molecular diagnostics to patients free of cost, has been proposed as a means of addressing this diagnostic inequity. Because of ethical concerns, many health systems have been reluctant to adopt IST even when it is available, particularly when sponsors are developing related therapeutics. This article examines the ethical and practical challenges associated with implementing IST in a clinic setting. Using hereditary variant transthyretin amyloidosis (ATTRv) as a case example, we assess when and how IST can expand access without undermining professional integrity, patient trust, or equitable care. We discuss recurrent ethical concerns surrounding IST, including conflicts of interest, data stewardship, fragmentation of medical records, inadequate education, clinician autonomy, and the risk of inappropriate testing in nonspecialist settings. We propose that IST is neither inherently ethical nor unethical, but rather that there are five conditions under which it may be incorporated appropriately into clinical practice. We conclude that adopting IST may offer a pragmatic solution to access issues in rare disease care, but it should not replace services that non-industry-sponsored, well-resourced, multidisciplinary care teams provide under clinical supervision. Sustainable and equitable diagnostic support will require broader structural transformations. Introduction Genetic testing is increasingly able to identify genetic variants that contribute to rare diseases. However, results from these tests can be confusing and challenging for patients to access, which is made more difficult by the well-recognized shortage of genetics specialists across the country.[i] In some regions, patients may be completely unable to receive the diagnostic services they require and deserve, even when testing would otherwise be covered by the health system. Industry-sponsored testing (IST)—sequencing and analysis that a commercial entity, such as a pharmaceutical company, provides without cost to the patient—is widely available and has been proposed as one strategy to address “diagnostic deserts” in underserved health systems.[ii] However, despite the availability of IST and these health systems’ capability to treat affected patients who have been tested, many healthcare providers have not adopted IST even where no public alternative exists. Reasons for this lack of adoption include staffing constraints, legal concerns, scope-of-practice limits, logistical and resource constraints, and ethical questions. Another reason for this lack of adoption may be that providers may attempt to follow institutional mandates by forgoing all gifts from industry. This adherence to policy reflects a legitimate ethical concern, but categorical refusal may limit patients’ access and clinicians’ ability to exercise beneficence in strict pursuit of institutional independence from industry. This leaves patients to self-advocate, pay out of pocket, endure misdiagnosis, or receive no diagnosis at all, potentially leading to worse health outcomes. It can also force clinicians to refer their patients to other health systems, interrupting continuity of care and imposing new barriers. Moreover, patients may choose not to complete a referral due to issues with insurance coverage, logistical requirements, physical burdens of traveling while ill, and diagnostic fatigue, among other reasons.[iii] Systems administrators, genetics specialists, and ethicists struggle to weigh the issues with the potential risks and benefits represented by IST. Very little has been written on the topic,[iv] but some reports suggest IST may increase uptake of clinically indicated testing[v] while other data demonstrate limitations in no-cost testing for improving uptake based on patient population demographics.[vi] Given the paucity of information, we use the case of hereditary variant transthyretin amyloidosis (ATTRv) to explore the ethical concerns of IST partnerships and the conditions under which those concerns may be overcome. Case Example Amyloidosis is a disorder in which amyloid protein accumulates pathologically in the body causing organ dysfunction. This protein accumulation is involved in the pathophysiology of many degenerative disorders.[vii] One form of amyloidosis is caused by transthyretin (TTR) protein, a normal protein predominantly made by the liver that transports thyroid hormone and retinol (vitamin A). ATTR has been associated with heart conditions, such as congestive heart failure, atrial fibrillation, and conduction abnormalities leading to the need for pacemakers. ATTR is also associated with musculoskeletal complaints including bilateral carpal tunnel syndrome, trigger finger, biceps tendon rupture, and joint arthritis, often requiring joint replacement at earlier ages. Neurological signs of ATTR include peripheral neuropathy, gait imbalances, and autonomic nervous system dysfunction. Early recognition of these symptoms as part of a systemic syndrome is critical, as treatment of the underlying amyloid protein deposition is required to manage these sequelae but does not reverse all the damage already done. ATTR can be subdivided into wild type (ATTRwt, formerly called senile ATTR), characterized by age-related protein misfolding, and hereditary variant (ATTRv), characterized by disease-causing genetic variants in the TTR gene. Once amyloidosis has been diagnosed, only genetic testing can distinguish ATTRwt from ATTRv. A correct, specific diagnosis between ATTRwt and ATTRv is critical, as ATTRv may have earlier onset and more systemic signs and symptoms. However, interpreting genetic results for this testing is complicated. Over 130 pathogenic variants within the TTR gene are associated with ATTRv, and each variant manifests differently across populations. Moreover, patients who are homozygous for a pathogenic variant may exhibit more severe symptoms at an earlier age. While treatment and prognosis are often dictated by the amount of cardiac and neurologic involvement, early genetic testing remains important as certain treatments may only be indicated for either ATTRv or ATTRwt. Different genetic variants are also associated with differing degrees of phenotypic penetrance: some primarily cause either cardiomyopathy or neuropathy while other genetic variants have mixed phenotypes. If a pathogenic variant is present, cascade genetic testing is recommended for first-degree family members, as there may be up to a 50 percent chance that they will be afflicted. Finally, genotyping may identify relatives at high risk of disease before they develop life-limiting cardiomyopathy and prevent irreversible disease progression. While expert opinion and guidelines recommend genetic testing for all patients diagnosed with ATTR[viii] regardless of patient demographics or severity of disease involvement, there are several reasons why genetic testing may not be performed. Patients affected by ATTR amyloidosis may be followed by a diverse team of clinicians. Currently, they are typically treated by advanced heart failure cardiologists and neurologists and are seen at tertiary academic centers of excellence, but this access and diagnostic bottleneck is improving. As the diagnostic pathway has been simplified and several FDA-approved treatments have become available, patients with amyloidosis are increasingly seen in community hospitals and placed under the care of nonspecialists. Because ATTR is a systemic condition, many other specialists may be involved in their care, including gastroenterologists, nephrologists, and orthopedists. In addition, genetics specialists may encounter the disease when screening for unrelated conditions and incidentally find an ATTR disease-causing variant. Industry-sponsored genetic test kits are available for use in diagnosing ATTRv. One example is the NavigATTR Sponsored Testing Program offered through PreventionGenetics, a program sponsored by AstraZeneca and Ionis Pharmaceuticals.[ix] Historically, these tests have not been widely recommended because of these programs’ relationship with their industry sponsors and concerns that the genetic information provided would be limited. However, IST kits offer an alternative route for diagnosis when this may not otherwise be available to affected patient populations. These IST kits are convenient to use and require only a cheek swab and postal drop-box. Some existing gaps in care stem from concerns about the ethics of industry partnerships rather than practical barriers to testing. The arguments for and against IST are outlined in Table 1 and discussed in detail below. See Table 1 (available in PDF version only) Health Systems’ Objections to Industry-Sponsored Testing Health systems may worry that integrating IST into ATTR workups involves a conflict of interest, particularly when testing is funded by companies developing ATTR therapeutics. Patients’ and providers’ distrust of industry involvement in medicine remains strong[x] and some administrators may worry that financial gain could motivate the sponsor’s offer. Even the mere appearance of such conflict can undermine the therapeutic relationship between patients and medical organizations.[xi] However, a commercial interest does not necessarily mean the relevant parties' interests are opposed. A sponsor seeking to identify patients who could benefit from a therapy may in fact share the clinician’s interest in diagnosis and the patient’s interest in receiving appropriate treatment. That said, a sponsor additionally benefits financially from identifying patients who are simultaneously potential customers. Patients who are unaware of such financial incentives may reasonably assume that IST has been recommended solely on clinical grounds. The sponsor need not and cannot completely eliminate these secondary gains, but they should not be allowed to influence clinical judgment. In addition, sponsors must adequately inform patients of sponsorship during the consent process. IST sponsors are not the only ones with conflicts. Clinicians may benefit from access to a diagnostic service that neither their patients nor their institution are required to pay for, which could lead them to favor IST even when alternative testing would be preferable from a purely clinical perspective. Health systems likewise have a financial interest in reducing the costs associated with genetic testing and benefit from transferring those costs to an industry sponsor. Each of these nonclinical incentives may impact which options are presented to patients and in what manner. Importantly, these conflicts need not improperly influence care. Rather, they can be managed through safeguards that preserve independent clinical judgment and informed patient consent. The ethical acceptability of IST therefore depends on the guidelines that institutions create and clinicians implement to protect patient and provider autonomy from inappropriate influence by secondary, nonclinical interests. The IST process also intrinsically changes access, workflow, and consistency of testing in ways that may not be equitable. In most clinical systems, laboratory medicine and pathology departments manage in-house testing, specimen processing, send-out validation, and the reporting of results into the electronic medical record (EMR). This oversight helps to improve consistency but often adds up to 300 percent to the original test cost.[xii] IST bypasses these workflows, avoiding that markup, but also bypasses institutional quality controls. Smaller hospitals and community health systems do not validate or endorse laboratories used by IST programs. In this model, ordering providers receive the results, often in their own email, and are then responsible for uploading those results into the EMR as a scanned document. This can result in lost or inaccessible results that undermine clinical utility and raise long-term stewardship concerns. IST therefore generates a new responsibility for already overburdened providers to continue consistent care. Likewise, because pending IST orders may not appear in the EMR, other providers during the key initial phase of workup may not see that testing has already been sent. Though genetics specialists are accustomed to searching for external reports in unfiltered documents, scanned documents, outside labs, or third-party digital portals, nonspecialists may be excluded from or unfamiliar with this digitized information. While this is mainly a practical challenge, the accessibility of IST results is also an ethical concern. Large-scope IST can cover dozens of genes associated with cardiomyopathy, but interpreting such large reports could quickly become overwhelming for nonspecialty clinics. Furthermore, each gene can have hundreds of variants of unclear significance in the literature. In addition, nonspecialist providers may not appreciate the nuances of comprehensive IST results. Finally, large-scope IST exacerbates ethical concerns related to patients’ privacy and data stewardship when large-scope materials are provided to industry partners. Conversely, disease-specific IST may be too narrow for some patients. A negative result on a panel designed around a particular diagnosis like ATTR does not exclude other genetic variations that may overlap phenotypes with the particular diagnosis tested for and clinicians unfamiliar with the test’s limitations may overinterpret a negative result as excluding a genetic etiology altogether. Broader panels or evaluation for phenotypically similar disorders may be more appropriate than provided IST in these cases. Clinical expertise is critical in selecting the most appropriate testing option for a specific patient’s case. Because of IST’s ready availability, increased testing may substantially tax already limited clinical resources available for ATTRv-positive patients. For instance, the most common TTR variant in the United States—p.V122I—is present in 3-4 percent of all individuals with African American ancestry.[xiii] Due to this significant incidence, referring patients for appropriate testing requires clinical experience and expertise. Over-testing this population could overwhelm specialty care dedicated to ATTR and early screening or population-level screening may not improve long-term outcomes. This suggests that if IST were given to every patient for every ATTR-like symptom, it could lead to erroneous diagnoses from false positive results and inappropriate interventions in patients who may never develop symptoms or need treatment. When IST provides useful clinical information, it can promote a robust patient–provider relationship. However, a significant increase in its use by nonspecialists would require clearer clinical guidance and access to scarce specialist support. Further clarification is needed about the ethical and medicolegal relationship IST creates between the sponsoring company, the clinician, and the patient. When a company provides the diagnostic test, patients may reasonably expect that company to provide additional resources such as psychoeducational support and facilitate referrals.[xiv] If these expectations are unmet, patients may experience emotional distress and confusion, potentially undertaking unrecommended action based on their misunderstanding. Clinicians may also feel implicit pressure to offer IST, particularly when programs are promoted as expanding access or as low-cost alternatives to other modes of testing as a solution to diagnostic deserts. This may cause them to worry that it intrudes on their professional authority and clinical judgment. Such pressure can limit the provider’s autonomy in making professional judgments of testing indications and their comfort with interpreting results. Ethical integration of IST therefore depends on preserving clinician discretion, which may require additional training and institutional support to prevent such pressures from interfering with professional judgment. Discussion The scarcity of public resources means that the state cannot always meet the healthcare needs of its citizens. Rare-disease communities vary widely in terms of what public support they receive, based in part on their capacity for self-advocacy.[xv] In this context, private enterprise can fill gaps in access to genetic testing created by these diagnostic deserts.[xvi] In this article, we have analyzed the case of ATTR to illustrate how IST may take up this role in an ethically robust way within particular parameters, and we believe these considerations are more broadly applicable to rare-disease testing. At the same time, the limitations of a streamlined IST approach must be acknowledged. Many clinical assessments offered by specialists add important context in interpreting these results and planning follow-up care. Cardiac and genetic specialists can identify at-risk relatives, differentiate similar conditions such as Fabry disease, order more inclusive testing when indicated, interpret equivocal results, and provide screening and management recommendations even in the setting of negative results. The unresolved challenge, therefore, is to weigh the value added by more accessible IST against the value added by multidisciplinary clinic-directed testing. Moreover, providers’ and patients’ attitudes toward these programs remain underexplored.[xvii] It is also important to recognize the structural conditions that have enabled and incentivized the current expansion of IST. Sponsorship is financially attractive for pharmaceutical companies during periods of active drug development, when they seek patients to benefit from their often-expensive treatments. If the provision of free testing depends on this incentive, IST cannot be guaranteed to future patients, and systems that rely on it will need strategies for maintaining access when market conditions inevitably change. Thus, although IST may remove the financial barrier to diagnosis for both patients and health systems at a given time, such relationships with industry must be established in a sustainable manner so as not to create a new form of vulnerability when the sponsor's market incentives change. Finally, studies increasingly demonstrate that no-cost genetic testing alone will not resolve racial disparities.[xviii] Addressing these disparities and other inequities will require the development of clinician- and patient-led ethical frameworks that guide the use of IST within conditions of scarcity and that ensure patients living with rare diseases receive appropriate, sustainable, and equitable diagnosis and care. The Way Forward The use of IST should be considered ethical when certain parameters are met. In Table 2, we identify five best-practice conditions to consider for the ethical incorporation of IST into a health system. See Table 2 (Available in PDF version only) IST can enhance patient autonomy by providing an additional diagnostic option where conventional testing is unavailable or unaffordable. However, providers must disclose sponsorship and discuss non-IST alternatives with patients as a part of the informed consent process. Offers of IST differ ethically from other testing options because they result from a third party with secondary commercial interests. Although commercial sponsorship does not make IST inherently unethical, the absence of cost and convenience of sponsored testing may also distort the choice situation. Therefore, respect for autonomy requires that IST be presented as one option among clinically appropriate alternatives as part of the informed-consent process, rather than as the default. Nonspecialists should rely on indications identified by specialists when determining whether an industry-sponsored test is clinically appropriate. Unnecessary testing can lead to ambiguous findings, misdiagnoses, inappropriate interventions, and anxiety. It further places additional demand on the already scarce resource of expertise. While targeted IST may provide benefits, blanket IST is not necessarily beneficial for patients and may unnecessarily expose their private health information to third parties, undermining their interest in privacy. IST should be conducted in a laboratory that meets all relevant clinical standards (such as CLIA certification), and the information it produces—including the written report—should also meet clinical and educational standards. It should satisfy the analytic reliability and clinical validity expected of similar diagnostic tests, as well as the requirement for plain language. We argue that an industry sponsor enters a specific ethical relationship with the patient when IST is performed. The sponsor therefore incurs some limited duties of care like a clinician. As sponsors derive potential benefit from providing testing to patients, the testing simultaneously generates foreseeable clinical needs for which sponsors should be responsible. These limited duties may reasonably include the provision of adequate pre- and post-test education, the reliable return of results, and the facilitation of follow-up care. Finally, because IST has both beneficial and burdensome impacts at the system level, the ethics of its utilization cannot be adequately addressed at the level of the individual encounter. Therefore, health systems that permit IST use have a duty to monitor the consequences of that choice and should revise their policies in response to those outcomes. A given relationship with a sponsor may be ethical at the time of establishment but must be continuously reevaluated as circumstances change, such as when alternative, non-sponsored testing options become available or follow-up capacity becomes overwhelmed. Conclusion While the concerns regarding IST presented in this commentary are reasonable, they must be weighed against the benefit of expanding access to critical genetic testing in diagnostic deserts. Rather than a blanket endorsement or prohibition, our conditional approval of IST offers a pragmatic approach to addressing these concerns. Nonetheless, IST should be understood as only one option for rare-disease diagnosis rather than a replacement for adequately resourced clinical care. Other models, including public benefit corporations, public-health models, the model of newborn screening, and licensing agreements that require access and affordability, should be considered, as has been argued in the context of genetic therapies.[xix] - [i] Maiese DR, Keehn A, Lyon M, Flannery D, Watson M. Current conditions in medical genetics practice. Genetics in Medicine. 2019;21(8):1874-1877. doi:10.1038/s41436-018-0417-6 [ii] Doyle TA, Conboy E, Halverson CME. Diagnostic deserts: Community‐level barriers to appropriate genetics services. American J of Med Genetics Pt A. Published online October 25, 2022:ajmg.a.63016. doi:10.1002/ajmg.a.63016 [iii] Doyle TA, Conboy E, Halverson CME. Diagnostic deserts: Community‐level barriers to appropriate genetics services. American J of Med Genetics Pt A. Published online October 25, 2022:ajmg.a.63016. doi:10.1002/ajmg.a.63016; Halverson CME, Clift KE, McCormick JB. Was it worth it? Patients’ perspectives on the perceived value of genomic-based individualized medicine. J Community Genet. 2016;7(2):145-152. doi:10.1007/s12687-016-0260-x [iv] Bartels K, Afonso S, Brown L, et al. Next generation of free? Points to consider when navigating sponsored genetic testing. J Med Genet. 2024;61(4):299-304. doi:10.1136/jmg-2023-109571 [v] Zhao PY, Branham K, Schlegel D, Fahim AT, Jayasundera KT. Association of No-Cost Genetic Testing Program Implementation and Patient Characteristics With Access to Genetic Testing for Inherited Retinal Degenerations. JAMA Ophthalmol. 2021;139(4):449. doi:10.1001/jamaophthalmol.2021.0004; Akbari H, Sunderraj A, Sanchez-Pinto N, Berg AT, George AL, Pardo AC. Genetic Testing and Hospital Length of Stay in Neonates With Epilepsy. Pediatric Neurology. 2022;133:30-33. doi:10.1016/j.pediatrneurol.2022.05.011; Leal‐Pardinas F, Truty R, McKnight DA, et al. Value of genetic testing for pediatric epilepsy: Driving earlier diagnosis of ceroid lipofuscinosis type 2 Batten disease. Epilepsia. 2022;63(7). doi:10.1111/epi.17269 [vi] Zhao PY, Branham K, Schlegel D, Fahim AT, Jayasundera KT. Association of No-Cost Genetic Testing Program Implementation and Patient Characteristics With Access to Genetic Testing for Inherited Retinal Degenerations. JAMA Ophthalmol. 2021;139(4):449. doi:10.1001/jamaophthalmol.2021.0004; Kassem NM, Althouse SK, Monahan PO, et al. Racial disparities in cascade testing for cancer predisposition genes. Preventive Medicine. 2023;172:107539. doi:10.1016/j.ypmed.2023.107539; Susswein LR, Skrzynia C, Lange LA, Booker JK, Graham ML, Evans JP. Increased Uptake of BRCA1/2 Genetic Testing Among African American Women With a Recent Diagnosis of Breast Cancer. JCO. 2008;26(1):32-36. doi:10.1200/JCO.2007.10.6377 [vii] Kittleson MM, Ruberg FL, Ambardekar AV, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis. Journal of the American College of Cardiology. 2023;81(11):1076-1126. doi:10.1016/j.jacc.2022.11.022 [viii] Kittleson MM, Ruberg FL, Ambardekar AV, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis. Journal of the American College of Cardiology. 2023;81(11):1076-1126. doi:10.1016/j.jacc.2022.11.022 [ix] Program overview. NavigATTR Sponsored Testing Program. 2026. https://www.preventiongenetics.com/tests/navigattr-sponsored-testing-program [x] Pahus L, Suehs CM, Halimi L, et al. Patient distrust in pharmaceutical companies: an explanation for women under-representation in respiratory clinical trials? BMC Med Ethics. 2020;21(1):72. doi:10.1186/s12910-020-00509-y [xi] Brody H. Professional Medical Organizations and Commercial Conflicts of Interest: Ethical Issues. The Annals of Family Medicine. 2010;8(4):354-358. doi:10.1370/afm.1140 [xii] Chang J, Sen AP, Boccuti C. Price Markups for Clinical Labs: Employer-based Insurance Pays Hospital Outpatient Departments 3X More Than Physician Offices and Independent Labs for Identical Tests. Health Care Cost Institute. Published online August 2, 2022. healthcostinstitute.org/hcci-research/price-markups-for-clinical-labs/ [xiii] Trachtenberg BH, Shah SK, Nussbaum RL, Bristow SL, Malladi R, Vatta M. Presence of the V122I Variant of Hereditary Transthyretin-Mediated Amyloidosis Among Self-Reported White Individuals in a Sponsored Genetic Testing Program. Circ: Genomic and Precision Medicine. 2021;14(5):e003466. doi:10.1161/CIRCGEN.121.003466 [xiv] Davey A, Rostant K, Harrop K, Goldblatt J, O’Leary P. Evaluating Genetic Counseling: Client Expectations, Psychological Adjustment and Satisfaction with Service. Journal of Genetic Counseling. 2005;14(3):197-206. doi:10.1007/s10897-005-0519-6 [xv] Halley MC, Halverson CME, Tabor HK. Rare Disease, Advocacy and Justice: Intersecting Disparities in Research and Clinical Care. [xvi] Doyle TA, Conboy E, Halverson CME. Diagnostic deserts: Community‐level barriers to appropriate genetics services. American J of Med Genetics Pt A. Published online October 25, 2022:ajmg.a.63016. doi:10.1002/ajmg.a.63016 [xvii] Bartels K, Afonso S, Brown L, et al. Next generation of free? Points to consider when navigating sponsored genetic testing. J Med Genet. 2024;61(4):299-304. doi:10.1136/jmg-2023-109571 [xviii] Zhao PY, Branham K, Schlegel D, Fahim AT, Jayasundera KT. Association of No-Cost Genetic Testing Program Implementation and Patient Characteristics With Access to Genetic Testing for Inherited Retinal Degenerations. JAMA Ophthalmol. 2021;139(4):449. doi:10.1001/jamaophthalmol.2021.0004 [xix] Kliegman M, Zaghlula M, Abrahamson S, et al. A roadmap for affordable genetic medicines. Nature. 2024;634(8033):307-314. doi:10.1038/s41586-024-07800-7
EUVIMED